ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

POZN Pozen, Inc. (MM)

5.94
0.00 (0.00%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pozen, Inc. (MM) NASDAQ:POZN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.94 0 01:00:00

Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers

19/10/2009 2:01pm

PR Newswire (US)


Pozen, Inc. (MM) (NASDAQ:POZN)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Pozen, Inc. (MM) Charts.
Results from PN400-301/302 studies presented at American College of Rheumatology Annual Scientific Meeting PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) and POZEN Inc. (NASDAQ:POZN) today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA. The data demonstrated that patients at risk for developing NSAID-associated gastric ulcers taking VIMOVO(TM) (naproxen/esomeprazole magnesium, formerly known as PN 400) experienced significantly fewer endoscopically confirmed gastric ulcers (GU) compared with patients taking enteric-coated (EC) naproxen (500 mg) alone. Data from study PN400-301 showed a 4.1% incidence of GU in patients taking VIMOVO, compared to 23.1% among patients taking EC naproxen (p

1 Year Pozen, Inc. (MM) Chart

1 Year Pozen, Inc. (MM) Chart

1 Month Pozen, Inc. (MM) Chart

1 Month Pozen, Inc. (MM) Chart